Acyclovir's Expanding Role: Five Therapeutic Uses That Go Well Beyond Cold Sores

Ask most Americans what acyclovir treats, and the answer will almost always involve cold sores or genital herpes. That association is understandable — these are among the most common reasons the medication is prescribed, and they are the uses most prominently featured on packaging and patient information leaflets. But acyclovir's story does not begin and end with herpes simplex.

Since its approval by the U.S. Food and Drug Administration, acyclovir has been studied and applied across a broader landscape of viral infections than many patients realize. For some people, learning about these additional uses is not merely interesting — it may be directly relevant to their own health situation or that of someone they care for. What follows is an informed look at five therapeutic applications of acyclovir that deserve wider recognition.

1. Chickenpox (Varicella) in High-Risk Patients

Chickenpox, caused by the varicella-zoster virus (VZV), is commonly thought of as a childhood rite of passage — uncomfortable but self-limiting. For most healthy children, that characterization is accurate. However, for adolescents, adults who have never been vaccinated or previously infected, pregnant individuals, and those with compromised immune systems, varicella can become a serious and even life-threatening illness.

In these higher-risk groups, acyclovir is an important therapeutic tool. When initiated within 24 hours of rash onset, oral acyclovir has been shown to reduce the duration and severity of symptoms, limit the number of lesions, and lower the risk of complications such as varicella pneumonia and bacterial superinfection. The standard adult dose for this indication — 800 mg four times daily for five days — is meaningfully different from the regimens used for HSV, reflecting both the nature of VZV and the clinical urgency of the situation.

For patients who are immunocompromised, intravenous acyclovir is often preferred, as it delivers higher drug concentrations more reliably. If you or someone in your household falls into a high-risk category and has been exposed to chickenpox, speaking with a healthcare provider promptly is advisable.

2. Prevention of Viral Reactivation in Transplant Recipients

Organ transplant recipients face a uniquely challenging medical reality. The immunosuppressive medications that prevent their bodies from rejecting a new organ simultaneously lower their defenses against infections — including viruses that may have been dormant for decades. HSV and VZV reactivations are among the most common viral complications following transplantation, and they can range from painful but manageable to severe and systemic.

Acyclovir is widely used as prophylactic therapy in this population, particularly in the weeks and months immediately following transplantation when immunosuppression is at its most intense. By maintaining a steady antiviral presence in the body, acyclovir can prevent these latent viruses from seizing the opportunity presented by a weakened immune system. In some transplant centers, prophylactic acyclovir is a standard part of post-operative care protocols, administered even before any signs of viral activity appear.

Patients preparing for a transplant, or those supporting a loved one through the process, may want to ask their transplant team about antiviral prophylaxis as part of the broader post-transplant care plan.

3. Management of Cytomegalovirus (CMV) — A Supporting Role

Cytomegalovirus is a member of the herpesvirus family that infects a substantial portion of the adult population without causing noticeable symptoms in healthy individuals. Like other herpesviruses, CMV establishes lifelong latency after initial infection and can reactivate when the immune system is suppressed. In transplant recipients, people living with HIV/AIDS, and others with significantly compromised immunity, CMV reactivation can cause serious complications including retinitis, pneumonitis, and gastrointestinal disease.

While acyclovir is not the first-line treatment for active CMV disease — medications such as ganciclovir and valganciclovir are more potent against this particular virus — high-dose oral acyclovir has been studied and used as a prophylactic agent in certain transplant populations to reduce the risk of CMV disease. Some clinical protocols have employed it specifically in kidney transplant recipients as a cost-effective preventive measure.

This is an area where patient awareness can make a difference. If you are immunocompromised and have never discussed CMV risk with your provider, it is a conversation worth initiating.

4. Herpes Encephalitis: A Neurological Emergency

Herpes encephalitis — inflammation of the brain caused by HSV-1 — is one of the most serious neurological emergencies associated with herpesvirus infections. It is rare, but when it occurs, it can cause rapid neurological deterioration, seizures, and permanent cognitive impairment if not treated immediately. Prior to the widespread availability of effective antiviral therapy, herpes encephalitis carried an extremely high mortality rate.

Intravenous acyclovir, administered at high doses for 14 to 21 days, is the established standard of care for this condition. Its ability to cross the blood-brain barrier — the protective membrane that limits what substances can enter the brain — makes it uniquely suited for this application. Early initiation of IV acyclovir has been shown to dramatically reduce both mortality and the severity of long-term neurological outcomes.

This is not a use most patients will ever encounter personally, but it illustrates an important point: acyclovir is not merely a comfort medication for minor outbreaks. In the right clinical context, it is a life-saving intervention. Understanding this broader scope helps patients appreciate that they are taking a medication with a serious and well-established medical legacy.

5. Neonatal Herpes: Protecting the Most Vulnerable Patients

Neonatal herpes — HSV infection transmitted to a newborn during delivery or, less commonly, in utero — represents one of the most urgent antiviral treatment scenarios in medicine. Newborns lack the mature immune defenses needed to contain herpesvirus infections, and untreated neonatal herpes can cause disseminated disease affecting multiple organ systems, including the brain, liver, and lungs. The consequences can be devastating.

Intravenous acyclovir is the cornerstone of treatment for neonatal herpes, and it is administered at weight-based doses over a course of 14 to 21 days depending on the extent of the infection. Research has also supported the use of oral acyclovir suppressive therapy following the initial treatment course to reduce the risk of neurological sequelae and recurrence.

For pregnant individuals with a known history of genital herpes, acyclovir or its prodrug valacyclovir may be prescribed during the final weeks of pregnancy to suppress viral shedding and reduce the risk of transmission to the newborn — a preventive application that underscores how broadly acyclovir's utility extends across the life spectrum.

A Medication With More Depth Than Its Reputation Suggests

Acyclovir's reputation as the go-to cold sore medication is not undeserved, but it tells only part of the story. From protecting newborns and transplant recipients to intervening in neurological emergencies, this antiviral has demonstrated clinical value across a range of conditions that most patients never associate with the small tube of cream in their medicine cabinet.

If you are currently prescribed acyclovir and have questions about why it was chosen for your specific situation, or if you believe you may benefit from antiviral therapy for a condition not typically discussed in standard patient materials, we encourage you to speak openly with your healthcare provider. Informed patients ask better questions — and better questions lead to better care.